Method for prediction of risk of malignant neoplasms development or diagnosis of malignant neoplasms in woman
SUBSTANCE: method for prediction of the risk of breast cancer development in a female individual that does not suffer from breast cancer, includes: determination of the level of pro-neurotensin 1-117 with amino acid sequence represented on SEQ ID No. 5, or its fragments from at least 5 amino acids or peptides containing this pro-neurotensin 1-117, obtained from the biological fluid of the specified female individual, selected from the group consisting of blood, serum, plasma, urine, cerebrospinal fluid and saliva, where pro-neurotensin 1-117 level is determined on an empty stomach; and correlation of the specified level of pro-neurotensin 1-117 or its fragments, or peptides containing pro-neurotensin 1-117, with the risk of breast cancer development, where an elevated level is prognostic for the increased risk of breast cancer.
EFFECT: method allows to effectively predict the risk of breast cancer development in a female individual.
14 cl, 2 dwg, 10 tbl, 5 ex
SUBSTANCE: blood serum anti-Mullerian hormone (AMH) is measured on the 3-5th day of the menstrual cycle by the immunoenzyme method, and an antral follicle count of 2-5 mm in diameter is derived on the 5-7th day of the menstrual cycle by means of transvaginal ultrasonic examination. The ovulatory menstrual cycles are predicted, if the measured AMH is from 5.0 to 8.0 ng/ml, while the antral follicle count in the ovary makes up to 10.
EFFECT: obtaining reliable results for the purpose of prescribing an adequate treatment in the adolescence and reproductive age aiming at detecting the ovulatory menstrual cycles and preventing endocrine sterility.
1 tbl, 2 ex
SUBSTANCE: serum hormones are measured on the second day of the menstrual cycle prior to peroral administering letrozole aromatase inhibitor 10 mg and 48 hours after; pre-letrozole oestradiol and anti-Mullerian hormone and post-letrozole oestradiol are measured. An absolute decrease of post-letrozole oestradiol is determined, and an ovarian aromatase activity coefficient (K) is determined by formula. If K <9.1, the low ovarian aromatase activity is determined, the 9.1<K<27.3 shows the normal activity, while K>27.3 - the high activity.
EFFECT: using the declared non-invasive method enables the high-accuracy assessment of the ovarian aromatase activity intensity.
5 tbl, 3 ex
SUBSTANCE: method involves measuring total blood thyroxin, conducting spinal X-ray osteodensitometry and spirometry, and measuring mineral bone density at the lumbar level of L2-L3, and maximal expiratory flow at 25% and 50% of respiratory function. The obtained data are used to calculate F by formula F=25.1-0.14×a1-15.7×a2+0.42×a3-0.034×a4, wherein 25.1 is a constant; 0.14; 15.7; 0.42; 0.034 are discriminant coefficients; a1, 2,…, 4 are numerical values of the conducted examination; a1 is the total thyroxin concentration, nmol/l; a2 is a bone L2-L3 density coefficient; a3 is the maximal expiratory flow at 25% according to respiratory function, %; a4 is the maximal expiratory flow at 50% according to respiratory function, %. If F is equal to or more than the constant, the patient is stated to have no signs of health situations specific for this type of industry; if F is less than the constant, the patient is referred to a risk group of health situations.
EFFECT: method enables detecting the incipient signs of health situations in workers.
1 tbl, 3 ex
SUBSTANCE: invention refers to medicine, namely to a method for detecting the synchronous tumour growth in the male patients suffering colon cancer. Substance of the invention consists in measuring preoperative blood testosterone and intestinal cell-stimulating hormone by Immunotech test systems (Czech Republic) in the male patients suffering colon cancer. Testosterone/intestinal cell-stimulating hormone ratio is calculated; if the derived value falls within the range of 0.45-2.18 enables stating the presence of single colon cancer, while the values within the range of 0.03-0.38 provides stating the presence of synchronous tumours.
EFFECT: using the declared method enables the more accurate preoperative detection of single or synchronous growth in the given category of patients.
SUBSTANCE: technique involves a blood serum examination for thyrotropic hormone, mcUnit/ml, free T4, pmole/l, prolactine, mIU/ml, follicle-stimulating hormone, mIU/ml, lutenizing hormone, mIU/ml, testosterone, nmole/l, dehydroepiandrosterone sulphate, mcg/ml, cortisol, nmole/l, oestradiol, pg/ml, 17-OH progesterone, nmole/l. Calculating an integral hormone state (HIS) by formula follows. If the HIS value is below 0.799, a habitual disorder is stated, which is accompanied by a minimum risk of the reproductive disorders. The HIS values falling from the range of 0.800 to 1.000 provides stating the tensed hormonal regulation reflecting a moderate risk of the reproductive disorders. The disturbed interhormonal cooperation corresponds to the HIS value falling within the range of 1.001 to ≤1.210 that represents a high risk of the reproductive disorders. The HIS value of more than 1.211 shows the lack of reserves that testifies to a very high risk of the reproductive disorders.
EFFECT: technique enables improving the diagnosis of the adolescent's reproductive disorders.
5 tbl, 3 ex
SUBSTANCE: for immature girls after day 3-5 of menstrual cycle a level of Anti-Mullerian Hormone is determined in blood serum by method of enzyme multiplied immunoassay (ELISA), and if its value exceeds 5.2 ng/ml the menstrual dysfunction is diagnosed against the background of polycystic ovarian syndrome.
EFFECT: use of specified method increases accuracy of diagnostics and execution of the appropriate remedial measures relating polycystic ovarian syndrome.
SUBSTANCE: method involves detecting a threatening miscarriage and a carrier state of the polymorphism in the gene of folate metabolism, as well as a CD54+ lymphocyte ratio, lactoferrin and β-subunit of human chorionic gonadotropin (β-HCG) levels in venous blood of a pregnant woman from the onset of pregnancy to the end of the first trimester. That is followed by calculating a prognostic index (PI) by formula: PI=0.7199X1+1.2552X2-0.00653X3-0.0009X4+0.0722X5+1.1277, wherein X1 is the threatening miscarriage, yes/no (1/0); X2 is the polymorphism in the gene of folate metabolism, yes/no (1/0); X3 is the CD54+ lymphocyte ratio, %; X4 is the lactoferrin level, ng/ml; X5 is the concentration of the free β-subunit of human chorionic gonadotropin (β-HCG), ng/ml. If PI<0, the gestational complications are predicted, while PI>0 enables stating a low risk of pathological conditions accompanying pregnancy. A sensitivity of the presented method makes 81.2%, its specificity is 85.1%. The method effectiveness is 83.2%.
EFFECT: method is minimally invasive, enables identifying a risk group of the gestational complications early that makes it possible to implement preventive measures aiming at preventing the pathological course of the pregnancy.
SUBSTANCE: invention refers to medicine. Substance of the early diagnostic technique for chronic renal disease consists in using a dosage range of dopamine of 1 to 3 mcg/kg of body weight and a standard water load of 200 ml. No glomerular filtration rate increase testifies to the presence of early signs of chronic renal disease.
EFFECT: using the declared technique enables standardising the examination as high as possible by precise dosage measurement of the preparation.
2 tbl, 2 ex
SUBSTANCE: first stage comprises a night suppressive test with dexamethasone 1 mg with a test considered to be positive, if plasma cortisol measured at 8.00 in the next morning exceeds 50 nmole/l. If the first stage has a positive result, the second stage is performed 1-2 days later. At the second stage, blood plasma cortisol at 24.00, daily urine free cortisol, a coefficient of circadian rhythm of cortisol secretion are determined on the same day. If at least two of the three test results are above normal: plasma cortisol at 24.00 is more than 207 nmole/l, daily urine free cortisol is more than 180 mcg/day, coefficient of circadian rhythm of cortisol secretion is more than 50%, hypercorticoidism syndrome is diagnosed. The presented technique provides higher accuracy and simplifies diagnosing of the given disease.
EFFECT: technique enables well-timed adequate therapeutic approach, prevents the disease transformation into manifestative hypercorticoidism with developing severe disabling complications.
SUBSTANCE: invention relates to the field of immunology, namely to enzyme-immunoassay, in particular to a method of detecting forms of vascular endothelial growth factor (VEGF) with a size more than 110 amino acids in a biological sample. The method includes the following stages: contact and incubation of the biological sample with an uptake reagent, immobilised on a solid substrate, where the uptake reagent contains a monoclonal antibody, which recognises and specifically binds with residues, in quantity more than 110, from human VEGF; separation of the biological sample from the immobilised uptake reagents; contact of the immobilised molecular complex of the reagent of the uptake-target with detected antibody, which binds with VEGF domains, responsible for binding with KDR and/or FLT1 receptor, or which binds with an epitope in VEGF1-110; measurement of the level of VEGF110+, bound with reagents of the uptake, with application of means of detection for the detected antibody. Set of immune assay reagents for detection of VEGF110+ forms in the biological sample. An antibody 5C3, obtained from hybridoma 5C3.1.1 with a depositary number PTA-7737, with the said antibody 5C3 binding VEGF110+ forms, including VEGF121+. Hybridoma 5C3.1.1, deposited in ATCC with the depositary number PTA-7737, to obtain the monoclonal antibody 5C3.
EFFECT: application of the claimed invention makes it possible to increase accuracy of detecting VEGF isoforms, which must not include isoform VEGF110 and must obligatory include isoform VEGF121.
25 cl, 3 dwg, 2 tbl, 1 ex
SUBSTANCE: presented group of inventions refers to medicine, molecular biology and biotechnology. A method for determining lung cancer cell sensitivity to cisplatin involving determining MLH1, ERCC1, DDB2, AKR1B1, FTL genes expression patterns vs. cisplatin IC50 for known cell lines; constructing cisplatin IC50 for these cell lines vs. derived gene expression patterns calibration straight, and hybridising on a microchip. What is also presented is a set of oligonucleotide probes presented by SEQ ID NO: 9-13.
EFFECT: presented group of inventions provides effective aids and methods for determining lung cancer cell sensitivity to cisplatin.
2 cl, 1 dwg, 2 tbl, 3 ex
SUBSTANCE: invention can be used for treating early breast cancer (BC) involving a radical mastectomy. To this effect, blood in an amount of 8-10 ml is sampled before the surgical intervention and on the first day following the surgical intervention to detect tumour cells. If the blood is found to contain circulating tumour cells on the first postoperative day with a zero level, the therapeutic setting is added with early postoperative FAC-based polychemotherapy.
EFFECT: invention enables assessing the activity of the tumour process accompanying BC and planning the further therapeutic approach.
SUBSTANCE: invention refers to medicine, namely to a method for determining a response to an anti-oestrogen therapy in the individuals suffering diagnosed breast cancer. Substance of the method for determining the response to the anti-oestrogen therapy in the individual suffering breast cancer consists in calculating an endocrine therapeutic index of circulating immune complexes (ETI-COC). If the ETI-COC falls within the range of 0-3, the favourable response to the anti-oestrogen therapy is stated, while the value of 4-6 shows the moderate response, and the value of 7-14 indicates the weak response.
EFFECT: using declared method enables determining the individual's response to the anti-oestrogen therapy effectively.
10 cl, 7 tbl, 8 dwg, 1 ex
SUBSTANCE: invention aims at detecting benign and malignant new growths in human thyroid. Involved thyroid and reference adjacent intact tissues are sampled; micro-RNA is recovered from the samples; that is followed by conducting a reverse transcription reaction, measuring an expression level of microRNA-21, -221, -222, -155, -205 by real-time RNA followed by a comparative analysis of the microRNA expression according to the norm and thyroid tumour involvement, and stating the presence and type of the new growth. If the above microRNA expression varies by no more than 4 times to the higher and lower figures of expression in relation to the reference, the benign new growth is stated. The malignant new growth is shown by the measured microRNA expression by more than 4 times.
EFFECT: effective detection of the benign and malignant thyroid new growths that promotes improving the further therapeutic approach.
5 dwg, 1 tbl, 4 ex
SUBSTANCE: present invention refers to medicine, namely to a method for detecting patients with progressing leukaemia and/or lymphoma and a risk of developing side effects of administering the CD19×CD3 bispecific antibody. A B:T cell ratio is measured in the patients; the ratio of 1:9 or less indicates the risk of possible side effects in the above patient. A dose schedule of the CD19×CD3 bispecific antibody provides: (a) administering the first dose of the CD19×CD3 bispecific antibody for the first time period; and then (b) administering the second dose of the above antibody for the second time period; the above second dose exceeds the above first dose.
EFFECT: using the given method enables facilitating the clinical course or preventing any side effect caused by administering the above bispecific antibody when treating the patients with leukaemia and/or lymphoma.
34 cl, 2 tbl, 9 ex
SUBSTANCE: invention refers to medicine, particularly to oncology, and aims at sub-typing breast cancer. RIL (PDLIM4) expression is measured in a patient's tumour tissue sample by the sequencing technology of the following NGS generation or by northern hybridisation methods and real-time PCR. If the RIL (PDLIM4) expression tends to decrease twice as much as its level in the normal tissues, a sub-type of a malignant breast new growth is diagnosed.
EFFECT: invention provides effective diagnostic technique for breast cancer subtype - tumours characterised by incomplete epithelial-mesenchymal transition and relatively minimally invasive.
2 dwg, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, pharmaceutics and biochemistry, and concerns a metastatic melanoma grade marker containing the amino acid sequence SEQ ID NO:1. There are also declared a recovered antibody and a monoclonal antibody, which recognise human TM9SF4 protein by binding to a peptide fragment of SEQ ID NO:1, as well as a kit for determining a tumour grade comprising the above antibody, using SEQ ID NO:1 for determining the metastatic pattern of melanoma.
EFFECT: group of inventions provides the faster detection of melanoma metastasis.
10 cl, 8 ex, 2 tbl, 10 dwg
SUBSTANCE: claimed group of inventions relates to the field of medicine, in particular to oncology and molecular biology. Claimed are a method and a set of primers and a probe with sequences SEQ ID NO: 1, 2 and 3 for the realisation of a polymerase chain reaction in a real time mode to diagnose clear cell renal cell carcinoma (CCRCC). The quantitative content of mRNA of the NETO2 gene is evaluated. In case of an increased content of mRNA in a supposedly cancer-affected human tissue in comparison with the quantity of mRNA in a healthy tissue, CCRCC is diagnosed.
EFFECT: claimed group of inventions makes it possible to diagnose CCRCC with high reliability, including an early stage of the tumour disease.
4 cl, 1 dwg, 5 tbl, 6 ex
SUBSTANCE: claimed group of inventions relates to the field of medicine, in particular to oncology and molecular biology. Claimed are a method and a set of primers and a probe with sequences SEQ ID NO: 1, 2 and 3 for the realisation of a polymerase chain reaction in a real time mode to diagnose clear cell renal cell carcinoma (CCRCC). The quantitative content of mRNA of the ACY1 gene is evaluated. In case of a reduced content of mRNA in a supposedly cancer-affected human tissue in comparison with the quantity of mRNA in a healthy tissue, CCRCC is diagnosed.
EFFECT: claimed group of inventions makes it possible to diagnose CCRCC with high reliability, including an early stage of the tumour disease.
4 cl, 1 dwg, 5 tbl, 6 ex
SUBSTANCE: invention refers to medicine, namely to immune therapy, and can be used to assess the efficacy of treating the patients suffering cancer. That is ensured by administering an immunogenic composition, which contains a recombinant viral vector expressing in vivo the whole MUC-1 antigen or a portion thereof. A method for analysing preparing a biological sample from a patient after the above immunogenic composition has been introduced, and measuring interferon γ in the sample. If interferon γ is more than approximately 4 pg/ml the patient is suggested to show the favourable clinical outcome.
EFFECT: invention assessing the clinical response to the cancer treatment in the patient.
15 cl, 3 dwg, 1 ex
SUBSTANCE: method involves carrying out immunohistochemical analysis of withdrawn tumor cells to determine percentage of cells showing Bax expression with respect to general quantity of cancer cells in vision field, percentage of cells showing Bcl-2 expression, index disclosing relation between the values. The index value being less than 1.0, high metastasis progress probability is to be predicted.
EFFECT: high accuracy of prognosis.